A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.
about
The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteinsEvidence for balancing selection from nucleotide sequence analyses of human G6PDThe evolution of vertebrate blood coagulation as viewed from a comparison of puffer fish and sea squirt genomesDefining 'full-length' recombinant factor VIII: a comparative structural analysis.Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.Purification and characterization of a new recombinant factor VIII (N8).APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant womenDelivery of factor VIII gene into skeletal muscle cells using lentiviral vector.Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia AStructural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysisElectron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments.Advancements in gene transfer-based therapy for hemophilia A.Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometryLack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIIINew-generation recombinant factor concentrates: bridge to gene therapy.The molecular basis of factor V and VIII procofactor activationMethylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolutionBlood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.Quantitative correlation between transcriptional levels of ER chaperone, peroximal protein and FVIII productivity in human Hek-293 cell lineGene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.The molecular basis of hemophilia A.piggyBac-mediated phenotypic correction of factor VIII deficiencyNonsense and missense mutations in hemophilia A: estimate of the relative mutation rate at CG dinucleotides.In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery.Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.Treating haemophilia A with recombinant blood factors: a comparison.Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loopA sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A miceTransgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIIIStable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based systemCharacterization of a genetically engineered inactivation-resistant coagulation factor VIIIaPlatelet-derived growth factor increases the in vivo activity of phospholipase C-gamma 1 and phospholipase C-gamma 2Engineering Factor Viii for Hemophilia Gene Therapy.Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variantHaemophilia therapies.O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII)Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles.
P2860
Q24296449-8FB9E620-52B1-40C1-BB32-907727C538CFQ24632302-3E567FDD-7184-4D09-9180-E4095C27CA9BQ24670412-ABC92907-642F-4AC2-95E5-0A98D52512FBQ30359132-78200CFE-6B0B-4622-B606-B5A524CE4646Q30493686-CCE17584-427A-4EDC-8B49-1DFC3CB002FAQ30881997-D4022AAD-C40F-4873-916B-5DECBF5BF126Q33538903-C9B0A797-FF70-4737-9BBB-F8FAC4E24ED1Q33565275-B3940E15-AB89-4239-ADD4-C62015247C61Q33688429-57A399E0-35C6-490C-9F7A-C3652CBB19D1Q33759739-4DE08CFE-CE49-46FF-A214-1EEB92B2D7A9Q33785902-81F52837-B598-4302-8183-DF71E2AC239EQ33923877-B59D0CA5-B17D-49BB-8AA3-0590E20429F3Q33962436-CDF2E2D3-17EA-43C5-9B9A-25BDE98C6E40Q34111482-1C5CEB3A-FC1C-429C-B561-4EFECFCB0F96Q34176033-39F6256A-2B39-486B-877F-2DC3BFFD0F01Q34358555-B283BE9F-E621-413A-AE9E-7445A628B1D6Q34387480-9FDDFD78-D2A1-4BFD-BCEB-24F4B3B089ECQ34404185-93D4A249-26F8-45ED-BA43-E2B904821B29Q34629632-6F743994-8621-49BE-B2AF-0A6621004ACBQ34675871-CDFD0C27-3106-49AB-BBFD-1DD11532688DQ34886372-78F2A1F4-790D-4E20-B45E-60E7F593E4BCQ35184221-F66EBB4B-AEE9-4029-A192-FEA539215D63Q35245535-41625979-7BC8-45E3-8DF7-B300C96BD92CQ35387018-D8CF942F-5AE5-475F-A5B3-16C0D72DBFBAQ35778288-BEB9CBCD-7EAA-4FCC-B5BF-EB83B174396AQ35779195-C68A569C-2FB7-4C71-867E-393A4CDE5285Q35791253-B2F84146-952D-4AB3-8702-BF0140EEECCEQ35804461-9AE20904-F255-40F0-9C84-A6EB344FF54CQ35849770-E2A640AE-D017-4BC8-94C5-96CC219CFD75Q36294629-1BDCE5F1-E9A9-4F26-A3CD-2791AE09F4F9Q36322576-4776EF62-929B-496D-A891-18250F405F3AQ36621449-5AFD2AE8-8D3C-447E-88F9-CABB7066EBC8Q36688353-260C9B35-5AF1-4FAE-8172-4E5B652D2372Q36737263-1013F92C-214C-49F3-A439-4E54FEFBEA68Q36797248-FF17698E-2AF6-40D9-8908-6CA73374CA4CQ36810282-76A67D60-D3E3-46B2-9071-36A0D094FB3DQ36950100-FE028C8B-DBDD-41B7-9F80-E9C743527FB4Q36974181-E7808F1E-091D-42E4-86ED-9A48A0A8F102Q37316242-735E69F1-C6C7-4B77-BFCB-437E4335AFD5Q37368521-FEFAF148-7667-4DA7-8CB6-54B594894B80
P2860
A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A large region (approximately ...... n vitro procoagulant activity.
@en
A large region
@nl
type
label
A large region (approximately ...... n vitro procoagulant activity.
@en
A large region
@nl
prefLabel
A large region (approximately ...... n vitro procoagulant activity.
@en
A large region
@nl
P2093
P2860
P356
P1476
A large region (approximately ...... n vitro procoagulant activity.
@en
P2093
P2860
P304
P356
10.1073/PNAS.83.16.5939
P407
P577
1986-08-01T00:00:00Z